ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 25, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - ESSA Pharma Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug masofaniten in combination with enzalutamide for prostate cancer treatment [3]. Group 1: Class Action Details - The class action represents investors who purchased ESSA Pharma securities between December 12, 2023, and October 31, 2024 [1]. - Investors have until March 25, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against ESSA Pharma - The complaint claims that ESSA Pharma made materially false and misleading statements about masofaniten's effectiveness when combined with enzalutamide, indicating no clear efficacy advantage over enzalutamide alone [3]. - The M-E Combination Study, which assessed masofaniten's performance, is unlikely to meet its primary endpoint as specified in Phase 2 [3]. - The company allegedly overstated masofaniten's clinical, regulatory, and commercial potential, leading to misleading public statements throughout the class period [3].